JP2013522238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522238A5 JP2013522238A5 JP2012557294A JP2012557294A JP2013522238A5 JP 2013522238 A5 JP2013522238 A5 JP 2013522238A5 JP 2012557294 A JP2012557294 A JP 2012557294A JP 2012557294 A JP2012557294 A JP 2012557294A JP 2013522238 A5 JP2013522238 A5 JP 2013522238A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- imidazo
- alkyl
- amine
- indazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3- (4- (tert-butyl) benzamido) -2-methylphenyl Chemical group 0.000 claims description 118
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 150000005829 chemical entities Chemical class 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 20
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 20
- 125000000335 thiazolyl group Chemical group 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 230000005764 inhibitory process Effects 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- CJWSQMSEHQXXCY-UHFFFAOYSA-N 1-[2-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-5-yl]ethanone Chemical compound N1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)C(=O)C)=C1 CJWSQMSEHQXXCY-UHFFFAOYSA-N 0.000 claims description 2
- AAHVXELFAIWJBK-UHFFFAOYSA-N 1-[4-[6-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 AAHVXELFAIWJBK-UHFFFAOYSA-N 0.000 claims description 2
- HHZJQTQNJPCNPC-UHFFFAOYSA-N 1-[4-[6-[[6-[3-(2-hydroxyethyl)-1h-indol-6-yl]imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=CN2C1=NC=C2 HHZJQTQNJPCNPC-UHFFFAOYSA-N 0.000 claims description 2
- AMKMRSDGPQZQLS-UHFFFAOYSA-N 1-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]-3-methylazetidin-3-ol Chemical compound C1C(C)(O)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 AMKMRSDGPQZQLS-UHFFFAOYSA-N 0.000 claims description 2
- UYCXAUWDQCPVMY-UHFFFAOYSA-N 1-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]-4-methylpiperidin-4-ol Chemical compound C1CC(C)(O)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 UYCXAUWDQCPVMY-UHFFFAOYSA-N 0.000 claims description 2
- MODZHSLQBONCHV-UHFFFAOYSA-N 1-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]azetidin-3-ol Chemical compound C1C(O)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 MODZHSLQBONCHV-UHFFFAOYSA-N 0.000 claims description 2
- IVHDGESMIPKUEO-UHFFFAOYSA-N 1-methyl-6-[5-methyl-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-3h-indol-2-one Chemical compound C1=C2N(C)C(=O)CC2=CC=C1C(=C(N1C=CN=C11)C)C=C1NC(N=C1)=CC=C1N1CCOCC1 IVHDGESMIPKUEO-UHFFFAOYSA-N 0.000 claims description 2
- VYICWLIDANWXNE-UHFFFAOYSA-N 2-[1-methyl-6-[5-methyl-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]indol-3-yl]ethanol Chemical compound C12=NC=CN2C(C)=C(C=2C=C3N(C)C=C(CCO)C3=CC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 VYICWLIDANWXNE-UHFFFAOYSA-N 0.000 claims description 2
- COXUVLHFSMGTNO-UHFFFAOYSA-N 2-[4-[[6-[3-(2-hydroxyethyl)-1h-indol-6-yl]imidazo[1,2-a]pyridin-8-yl]amino]phenyl]-2-methylpropan-1-ol Chemical compound C1=CC(C(C)(CO)C)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=CN2C1=NC=C2 COXUVLHFSMGTNO-UHFFFAOYSA-N 0.000 claims description 2
- QWHKXQBDXJJCHD-UHFFFAOYSA-N 2-[5-methyl-3-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyrazol-1-yl]ethanol Chemical compound OCCN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=NC=2)=N1 QWHKXQBDXJJCHD-UHFFFAOYSA-N 0.000 claims description 2
- LUWFEEPUDGWECA-UHFFFAOYSA-N 2-[6-[5-chloro-8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1-methylindol-3-yl]ethanol Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3N(C)C=C(CCO)C3=CC=2)=C(Cl)N2C1=NC=C2 LUWFEEPUDGWECA-UHFFFAOYSA-N 0.000 claims description 2
- WCSIPHYOIZRNNZ-UHFFFAOYSA-N 2-[6-[5-chloro-8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=C(Cl)N2C1=NC=C2 WCSIPHYOIZRNNZ-UHFFFAOYSA-N 0.000 claims description 2
- CPYZUOJAUGIHIA-UHFFFAOYSA-N 2-[6-[5-chloro-8-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1-methylindol-3-yl]ethanol Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3N(C)C=C(CCO)C3=CC=2)=C(Cl)N2C1=NC=C2 CPYZUOJAUGIHIA-UHFFFAOYSA-N 0.000 claims description 2
- OEZWQIKWWVKAJI-UHFFFAOYSA-N 2-[6-[5-chloro-8-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=C(Cl)N2C1=NC=C2 OEZWQIKWWVKAJI-UHFFFAOYSA-N 0.000 claims description 2
- UJLCAUDXTUPBJP-UHFFFAOYSA-N 2-[6-[8-(6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)imidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C1=C2COCCN2N=C1NC1=CC(C=2C=C3NC=C(C3=CC=2)CCO)=CN2C=CN=C21 UJLCAUDXTUPBJP-UHFFFAOYSA-N 0.000 claims description 2
- XMRNHTWGJJNSMS-UHFFFAOYSA-N 2-[6-[8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C=1C=C2C(CCO)=CNC2=CC=1C(=CN1C=CN=C11)C=C1NC(N=C1)=CC=C1N1CCOCC1 XMRNHTWGJJNSMS-UHFFFAOYSA-N 0.000 claims description 2
- QSKNZFLYYGWRJV-UHFFFAOYSA-N 2-[6-[8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-yl]ethanol Chemical compound C1CC2C(CCO)NNC2CC1C(=CN1C=CN=C11)C=C1NC(N=C1)=CC=C1N1CCOCC1 QSKNZFLYYGWRJV-UHFFFAOYSA-N 0.000 claims description 2
- VMJQTHKIUMLGNI-UHFFFAOYSA-N 2-[6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]-5-methylimidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=C(C)N2C1=NC=C2 VMJQTHKIUMLGNI-UHFFFAOYSA-N 0.000 claims description 2
- OHRHYLMKOWOKNP-UHFFFAOYSA-N 2-[6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-yl]ethanol Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C2CC3NNC(CCO)C3CC2)=CN2C1=NC=C2 OHRHYLMKOWOKNP-UHFFFAOYSA-N 0.000 claims description 2
- XIQBMHMYQXKVNB-UHFFFAOYSA-N 2-[ethyl-[6-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]amino]ethanol Chemical compound N1=CC(N(CCO)CC)=CC=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 XIQBMHMYQXKVNB-UHFFFAOYSA-N 0.000 claims description 2
- XLWBHWLYRXBZRX-UHFFFAOYSA-N 2-hydroxy-1-[4-[6-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)CO)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 XLWBHWLYRXBZRX-UHFFFAOYSA-N 0.000 claims description 2
- GVZHUWSLJZJBOW-UHFFFAOYSA-N 2-n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]-5-n-(2-methoxyethyl)-5-n-methylpyridine-2,5-diamine Chemical compound N1=CC(N(C)CCOC)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 GVZHUWSLJZJBOW-UHFFFAOYSA-N 0.000 claims description 2
- KEZHRKOVLKUYCQ-UHFFFAOYSA-N 3,3-dimethyl-1h-indol-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)NC2=C1 KEZHRKOVLKUYCQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- ARLTZSGJPGABLS-UHFFFAOYSA-N 3-(2-hydroxyethyl)-6-[8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1h-benzimidazol-2-one Chemical compound C1=C2NC(=O)N(CCO)C2=CC=C1C(=CN1C=CN=C11)C=C1NC(N=C1)=CC=C1N1CCOCC1 ARLTZSGJPGABLS-UHFFFAOYSA-N 0.000 claims description 2
- TTXXVRQVMWILOX-UHFFFAOYSA-N 5-chloro-n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=C(Cl)N2C1=NC=C2 TTXXVRQVMWILOX-UHFFFAOYSA-N 0.000 claims description 2
- JCGQOBWKAYVSHM-UHFFFAOYSA-N 5-chloro-n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=CC=2)=C(Cl)N2C1=NC=C2 JCGQOBWKAYVSHM-UHFFFAOYSA-N 0.000 claims description 2
- NGNYRZRWQFOUFK-UHFFFAOYSA-N 5-ethyl-n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=C(CC)N2C1=NC=C2 NGNYRZRWQFOUFK-UHFFFAOYSA-N 0.000 claims description 2
- HYULMKQXSAMIIE-UHFFFAOYSA-N 5-ethyl-n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=CC=2)=C(CC)N2C1=NC=C2 HYULMKQXSAMIIE-UHFFFAOYSA-N 0.000 claims description 2
- SMDZKFNTPDKVCD-UHFFFAOYSA-N 5-methyl-n-(5-morpholin-4-ylpyridin-2-yl)-6-(1h-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC=CN2C(C)=C(C=2C=C3C=CNC3=NC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 SMDZKFNTPDKVCD-UHFFFAOYSA-N 0.000 claims description 2
- VVVAHIMKXLXSAZ-UHFFFAOYSA-N 5-methyl-n-[6-(1h-pyrazolo[4,3-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-amine Chemical compound N1=C2C=NNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)C)=C1 VVVAHIMKXLXSAZ-UHFFFAOYSA-N 0.000 claims description 2
- XGIBBFYEAXESGG-UHFFFAOYSA-N 5-methylsulfonyl-n-[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-amine Chemical compound N1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)S(=O)(=O)C)=C1 XGIBBFYEAXESGG-UHFFFAOYSA-N 0.000 claims description 2
- HFLJFLGBUYZUQI-UHFFFAOYSA-N 6-(1,3-benzothiazol-5-yl)-n-(5,6-dimethoxypyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3N=CSC3=CC=2)=CN2C1=NC=C2 HFLJFLGBUYZUQI-UHFFFAOYSA-N 0.000 claims description 2
- VNVXBPDUZLOFDL-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridine-5-carboxylic acid Chemical compound C12=NC=CN2C(C(=O)O)=C(C=2C=C3NN=CC3=CC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 VNVXBPDUZLOFDL-UHFFFAOYSA-N 0.000 claims description 2
- MMVVVHCESUZDJQ-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(1-methylpyrazol-3-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=N1 MMVVVHCESUZDJQ-UHFFFAOYSA-N 0.000 claims description 2
- RXLYIOCBKNBFKY-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(2-methoxypyrimidin-4-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound COC1=NC=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=N1 RXLYIOCBKNBFKY-UHFFFAOYSA-N 0.000 claims description 2
- ASOHWEMFUOHJIO-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(5-morpholin-4-ylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1COCCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 ASOHWEMFUOHJIO-UHFFFAOYSA-N 0.000 claims description 2
- SMDZVMZCRFMZLC-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(6-morpholin-4-ylpyridazin-3-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1COCCN1C(N=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 SMDZVMZCRFMZLC-UHFFFAOYSA-N 0.000 claims description 2
- ZWZYOUWAHJEIEO-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-pyrimidin-4-ylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C(C=2C=C3NN=CC3=CC=2)=CN2C=CN=C2C=1NC1=CC=NC=N1 ZWZYOUWAHJEIEO-UHFFFAOYSA-N 0.000 claims description 2
- OPBMELYINMFWHW-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-5-chloro-N-[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]imidazo[1,2-a]pyridin-8-amine Chemical compound CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=CC(=C(N4C3=NC=C4)Cl)C5CCC6CNNC6C5 OPBMELYINMFWHW-UHFFFAOYSA-N 0.000 claims description 2
- AVVSZNQPPXNDTD-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-5-fluoro-N-[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]imidazo[1,2-a]pyridin-8-amine Chemical compound CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=CC(=C(N4C3=NC=C4)F)C5CCC6CNNC6C5 AVVSZNQPPXNDTD-UHFFFAOYSA-N 0.000 claims description 2
- ZUALLIRHZKQFCS-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-5-methyl-N-(5-morpholin-4-ylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CC1=C(C=C(C2=NC=CN12)NC3=NC=C(C=C3)N4CCOCC4)C5CCC6CNNC6C5 ZUALLIRHZKQFCS-UHFFFAOYSA-N 0.000 claims description 2
- POQYKNCZHZAFJV-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridine-5-carboxamide Chemical compound C1CC2CNNC2CC1C3=C(N4C=CN=C4C(=C3)NC5=NC=C(C=C5)N6CCOCC6)C(=O)N POQYKNCZHZAFJV-UHFFFAOYSA-N 0.000 claims description 2
- WKMHWRRKVGSIQB-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)-n-(1,5-dimethylpyrazol-3-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NCCOC3=CC=2)=N1 WKMHWRRKVGSIQB-UHFFFAOYSA-N 0.000 claims description 2
- TVEGHVLNCAEJCT-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)-n-(5,6-dimethoxypyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3NCCOC3=CC=2)=CN2C1=NC=C2 TVEGHVLNCAEJCT-UHFFFAOYSA-N 0.000 claims description 2
- GVROMDVQUCKWGE-UHFFFAOYSA-N 6-[5-chloro-8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=C(Cl)N2C1=NC=C2 GVROMDVQUCKWGE-UHFFFAOYSA-N 0.000 claims description 2
- QWTXOMHDNPKELH-UHFFFAOYSA-N 6-[5-chloro-8-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=C(Cl)N2C1=NC=C2 QWTXOMHDNPKELH-UHFFFAOYSA-N 0.000 claims description 2
- UNYZBRTVGVYOPI-UHFFFAOYSA-N 6-[5-ethyl-8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=C(CC)N2C1=NC=C2 UNYZBRTVGVYOPI-UHFFFAOYSA-N 0.000 claims description 2
- VUUURTUOFFIMSH-UHFFFAOYSA-N 6-[8-(6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-5-methylimidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2CC(=O)NC2=CC(C2=C(N3C=CN=C3C(NC3=NN4CCOCC4=C3)=C2)C)=C1 VUUURTUOFFIMSH-UHFFFAOYSA-N 0.000 claims description 2
- KUGHIXMRCSFERL-UHFFFAOYSA-N 6-[8-(6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2COCCN2N=C1NC1=CC(C2=CC=C3CC(NC3=C2)=O)=CN2C=CN=C21 KUGHIXMRCSFERL-UHFFFAOYSA-N 0.000 claims description 2
- AIZDDANRTXKWHE-UHFFFAOYSA-N 6-[8-[(1-ethylpyrazol-3-yl)amino]imidazo[1,2-a]pyridin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound CCN1C=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC(=O)COC3=CC=2)=N1 AIZDDANRTXKWHE-UHFFFAOYSA-N 0.000 claims description 2
- WDFOWXGTQYELBY-UHFFFAOYSA-N 6-[8-[(1-ethylpyrazol-3-yl)amino]imidazo[1,2-a]pyridin-6-yl]quinazolin-2-amine Chemical compound CCN1C=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3C=NC(N)=NC3=CC=2)=N1 WDFOWXGTQYELBY-UHFFFAOYSA-N 0.000 claims description 2
- AWKDVPHOKZABMA-UHFFFAOYSA-N 6-[8-[(5,6-dimethoxypyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1h-indazol-3-amine Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3NN=C(N)C3=CC=2)=CN2C1=NC=C2 AWKDVPHOKZABMA-UHFFFAOYSA-N 0.000 claims description 2
- HHKKVEQGIUFVDE-UHFFFAOYSA-N 6-[8-[(5-acetyl-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2CC(=O)NC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)C(=O)C)=C1 HHKKVEQGIUFVDE-UHFFFAOYSA-N 0.000 claims description 2
- BGWCPJXCPBYEGZ-UHFFFAOYSA-N 6-[8-[(5-methylsulfonyl-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2CC(=O)NC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)S(=O)(=O)C)=C1 BGWCPJXCPBYEGZ-UHFFFAOYSA-N 0.000 claims description 2
- QZYWXLJTMHJVDD-UHFFFAOYSA-N 6-[8-[(6-morpholin-4-ylpyridazin-3-yl)amino]imidazo[1,2-a]pyridin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)COC2=CC=C1C(=CN1C=CN=C11)C=C1NC(N=N1)=CC=C1N1CCOCC1 QZYWXLJTMHJVDD-UHFFFAOYSA-N 0.000 claims description 2
- ALPRTTKLDJFBBW-UHFFFAOYSA-N 6-[8-[[1-(2-hydroxyethyl)-5-methylpyrazol-3-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound OCCN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC(=O)CC3=CC=2)=N1 ALPRTTKLDJFBBW-UHFFFAOYSA-N 0.000 claims description 2
- ZURICCOPZVTCKC-UHFFFAOYSA-N 6-[8-[[5-(1-hydroxy-2-methylpropan-2-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound N1=CC(C(C)(CO)C)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=CN2C1=NC=C2 ZURICCOPZVTCKC-UHFFFAOYSA-N 0.000 claims description 2
- MUWCGKRRJVQKKE-UHFFFAOYSA-N 6-[8-[[5-(2-hydroxypropan-2-yl)-1-methylpyrazol-3-yl]amino]imidazo[1,2-a]pyridin-6-yl]-3-methyl-1h-benzimidazol-2-one Chemical compound C1=C(C(C)(C)O)N(C)N=C1NC1=CC(C=2C=C3NC(=O)N(C)C3=CC=2)=CN2C1=NC=C2 MUWCGKRRJVQKKE-UHFFFAOYSA-N 0.000 claims description 2
- ITTZAVWEURMZDA-UHFFFAOYSA-N 6-[8-[[5-(4-acetylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=CN2C1=NC=C2 ITTZAVWEURMZDA-UHFFFAOYSA-N 0.000 claims description 2
- BNBHTSNPZVCWIT-UHFFFAOYSA-N 6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]-5-methylimidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=C(C)N2C1=NC=C2 BNBHTSNPZVCWIT-UHFFFAOYSA-N 0.000 claims description 2
- VZYWHPBXQSDYJO-UHFFFAOYSA-N 6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]-5-methylimidazo[1,2-a]pyridin-6-yl]-3-(2-methoxyethyl)-1h-benzimidazol-2-one Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)N(CCOC)C3=CC=2)=C(C)N2C1=NC=C2 VZYWHPBXQSDYJO-UHFFFAOYSA-N 0.000 claims description 2
- CYNCIMVWMPLNDR-UHFFFAOYSA-N 6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]-5-methylimidazo[1,2-a]pyridin-6-yl]-n-methyl-1h-indole-3-carboxamide Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(C3=CC=2)C(=O)NC)=C(C)N2C1=NC=C2 CYNCIMVWMPLNDR-UHFFFAOYSA-N 0.000 claims description 2
- ZZHTYBPWEZHTGD-UHFFFAOYSA-N 6-[8-[[5-(hydroxymethyl)-1-methylpyrazol-3-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C(CO)N(C)N=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=CN2C1=NC=C2 ZZHTYBPWEZHTGD-UHFFFAOYSA-N 0.000 claims description 2
- PNUYPAFIVQXTMN-UHFFFAOYSA-N 6-n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]pyridine-2,6-diamine Chemical compound NC1=CC=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=N1 PNUYPAFIVQXTMN-UHFFFAOYSA-N 0.000 claims description 2
- BRLWIFKLTDXPIT-UHFFFAOYSA-N 6-phenyl-n-pyridin-2-ylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C(C=2C=CC=CC=2)=CN2C=CN=C2C=1NC1=CC=CC=N1 BRLWIFKLTDXPIT-UHFFFAOYSA-N 0.000 claims description 2
- XPKXLBASWYFXNT-UHFFFAOYSA-N 7-[8-[(5,6-dimethoxypyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1h-quinoxalin-2-one Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3N=C(O)C=NC3=CC=2)=CN2C1=NC=C2 XPKXLBASWYFXNT-UHFFFAOYSA-N 0.000 claims description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- LISFXZADUDULQH-UHFFFAOYSA-N C1(CC1)C1=CC(=NN1)NC=1C=2N(C=C(C=1)N1C(CC3=CC=CC=C13)=O)C=CN=2 Chemical compound C1(CC1)C1=CC(=NN1)NC=1C=2N(C=C(C=1)N1C(CC3=CC=CC=C13)=O)C=CN=2 LISFXZADUDULQH-UHFFFAOYSA-N 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- YMHITOQTVDEFGO-UHFFFAOYSA-N ClC1=C(C=C(C=2N1C=CN=2)NC1=NC=C(C=C1)N1CCN(CC1)C(C)C)N1C(N(C2=C1C=CC=C2)CCOC)=O Chemical compound ClC1=C(C=C(C=2N1C=CN=2)NC1=NC=C(C=C1)N1CCN(CC1)C(C)C)N1C(N(C2=C1C=CC=C2)CCOC)=O YMHITOQTVDEFGO-UHFFFAOYSA-N 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- RVSYYOCTUBFIEA-HXUWFJFHSA-N [(2r)-4-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]morpholin-2-yl]methanol Chemical compound C1CO[C@@H](CO)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 RVSYYOCTUBFIEA-HXUWFJFHSA-N 0.000 claims description 2
- RVSYYOCTUBFIEA-FQEVSTJZSA-N [(2s)-4-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]morpholin-2-yl]methanol Chemical compound C1CO[C@H](CO)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 RVSYYOCTUBFIEA-FQEVSTJZSA-N 0.000 claims description 2
- YEYVGVKGXYMVCC-UHFFFAOYSA-N [2-methyl-5-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyrazol-3-yl]methanol Chemical compound C1=C(CO)N(C)N=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 YEYVGVKGXYMVCC-UHFFFAOYSA-N 0.000 claims description 2
- VGNNTCALLGKSHX-UHFFFAOYSA-N [6-(1h-indazol-6-yl)-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-5-yl]methanol Chemical compound C12=NC=CN2C(CO)=C(C=2C=C3NN=CC3=CC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 VGNNTCALLGKSHX-UHFFFAOYSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- YVGHEDFSVFTXPY-UHFFFAOYSA-N n-(1,5-dimethylpyrazol-3-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=N1 YVGHEDFSVFTXPY-UHFFFAOYSA-N 0.000 claims description 2
- HAJVAUCPWNZZGX-UHFFFAOYSA-N n-(1,5-dimethylpyrazol-3-yl)-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=NC=2)=N1 HAJVAUCPWNZZGX-UHFFFAOYSA-N 0.000 claims description 2
- XMUVBXMTSPNLPS-UHFFFAOYSA-N n-(1-ethyl-5-methylpyrazol-3-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1=C(C)N(CC)N=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XMUVBXMTSPNLPS-UHFFFAOYSA-N 0.000 claims description 2
- QZKWYFPIFQWRHS-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=NC=2)=N1 QZKWYFPIFQWRHS-UHFFFAOYSA-N 0.000 claims description 2
- SYSJQJZIAWYOMV-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 SYSJQJZIAWYOMV-UHFFFAOYSA-N 0.000 claims description 2
- SRFSZFSWBWSJQH-UHFFFAOYSA-N n-(5,6-dimethoxypyridin-2-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 SRFSZFSWBWSJQH-UHFFFAOYSA-N 0.000 claims description 2
- YXTJUKDGLBHAFK-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CC1C1=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=NN1 YXTJUKDGLBHAFK-UHFFFAOYSA-N 0.000 claims description 2
- RCLXJYDRYVESJQ-UHFFFAOYSA-N n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-5-methyl-6-(2-methyl-1h-indol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(C)=CC3=CC=2)=C(C)N2C1=NC=C2 RCLXJYDRYVESJQ-UHFFFAOYSA-N 0.000 claims description 2
- UBPVTSSZDKOYFK-UHFFFAOYSA-N n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indazol-6-yl)-5-methylimidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=C(C)N2C1=NC=C2 UBPVTSSZDKOYFK-UHFFFAOYSA-N 0.000 claims description 2
- LGGCHDONPKSGDE-UHFFFAOYSA-N n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indol-6-yl)-5-methylimidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=CC=2)=C(C)N2C1=NC=C2 LGGCHDONPKSGDE-UHFFFAOYSA-N 0.000 claims description 2
- CMHPYDOBMCOOAH-UHFFFAOYSA-N n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 CMHPYDOBMCOOAH-UHFFFAOYSA-N 0.000 claims description 2
- FDSOXFJXLFBPIZ-UHFFFAOYSA-N n-[5-(methoxymethyl)-1-methylpyrazol-3-yl]-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C(COC)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=NC=2)=N1 FDSOXFJXLFBPIZ-UHFFFAOYSA-N 0.000 claims description 2
- HZTAVSLVUIIUGL-UHFFFAOYSA-N n-[5-methyl-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound N1=C2C=CNC2=CC(C2=C(N3C=CN=C3C(NC3=NN4CCOCC4=C3)=C2)C)=C1 HZTAVSLVUIIUGL-UHFFFAOYSA-N 0.000 claims description 2
- BPVLQNSUUBLGQQ-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)-5-methylimidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound C1=C2C=NNC2=CC(C2=C(N3C=CN=C3C(NC3=NN4CCOCC4=C3)=C2)C)=C1 BPVLQNSUUBLGQQ-UHFFFAOYSA-N 0.000 claims description 2
- KAMBVFJWGKNGER-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]-2-morpholin-4-yl-1,3-thiazol-4-amine Chemical compound C1COCCN1C1=NC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=CS1 KAMBVFJWGKNGER-UHFFFAOYSA-N 0.000 claims description 2
- ZZQOQJADXKUIPJ-UHFFFAOYSA-N n-[6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-yl]-5-methyl-1,2-oxazol-3-amine Chemical compound O1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=CC=2)=N1 ZZQOQJADXKUIPJ-UHFFFAOYSA-N 0.000 claims description 2
- ONWRETPOJYEBFC-UHFFFAOYSA-N n-[6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-yl]-5-methyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-2-amine Chemical compound C1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NC=3CCN(CC=3S2)C)=C1 ONWRETPOJYEBFC-UHFFFAOYSA-N 0.000 claims description 2
- PYORNTJWSPQNLQ-UHFFFAOYSA-N n-[6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound C1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCOCC3=C2)=C1 PYORNTJWSPQNLQ-UHFFFAOYSA-N 0.000 claims description 2
- GVICIFRDMKTFNW-UHFFFAOYSA-N n-[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound N1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCOCC3=C2)=C1 GVICIFRDMKTFNW-UHFFFAOYSA-N 0.000 claims description 2
- GBBHSMOHDUTCDP-UHFFFAOYSA-N n-[6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound C1=C2COCCN2N=C1NC1=CC(C2=CC=C3OCCNC3=C2)=CN2C=CN=C21 GBBHSMOHDUTCDP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- ORNSLMJWQDGQFF-UHFFFAOYSA-N 1h-pyrido[2,3-b][1,4]oxazin-2-one Chemical compound C1=CC=C2NC(=O)COC2=N1 ORNSLMJWQDGQFF-UHFFFAOYSA-N 0.000 claims 1
- KSRWGJRHJUQFTH-UHFFFAOYSA-N 3-morpholin-4-ylpyridin-2-amine Chemical compound NC1=NC=CC=C1N1CCOCC1 KSRWGJRHJUQFTH-UHFFFAOYSA-N 0.000 claims 1
- SUUKTILQMGAGMW-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-5-methyl-N-(5-piperazin-1-ylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CC1=C(C=C(C2=NC=CN12)NC3=NC=C(C=C3)N4CCNCC4)C5CCC6CNNC6C5 SUUKTILQMGAGMW-UHFFFAOYSA-N 0.000 claims 1
- IDHJCPFMQJVVJT-UHFFFAOYSA-N 6-[8-[[5-(2-hydroxypropan-2-yl)-1-methylpyrazol-3-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C(C(C)(C)O)N(C)N=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=CN2C1=NC=C2 IDHJCPFMQJVVJT-UHFFFAOYSA-N 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- XRCXMMOXQGZKBD-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound C1=C2C=NNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCOCC3=C2)=C1 XRCXMMOXQGZKBD-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 0 *c(cc1N*)c(*)[n]2c1ncc2 Chemical compound *c(cc1N*)c(*)[n]2c1ncc2 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- AGCIFROCRUWKFH-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-5-methyl-n-(5-piperazin-1-ylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC=CN2C(C)=C(C=2C=C3NN=CC3=CC=2)C=C1NC(N=C1)=CC=C1N1CCNCC1 AGCIFROCRUWKFH-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- NABGSOKMSDXZLC-UHFFFAOYSA-N methyl 6-(1h-indazol-6-yl)-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridine-5-carboxylate Chemical compound C12=NC=CN2C(C(=O)OC)=C(C=2C=C3NN=CC3=CC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 NABGSOKMSDXZLC-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31277110P | 2010-03-11 | 2010-03-11 | |
| US61/312,771 | 2010-03-11 | ||
| US31322310P | 2010-03-12 | 2010-03-12 | |
| US61/313,223 | 2010-03-12 | ||
| PCT/US2011/028194 WO2011112995A1 (en) | 2010-03-11 | 2011-03-11 | Imidazopyridines syk inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015094508A Division JP6177828B2 (ja) | 2010-03-11 | 2015-05-05 | イミダゾピリジンｓｙｋ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522238A JP2013522238A (ja) | 2013-06-13 |
| JP2013522238A5 true JP2013522238A5 (enExample) | 2014-05-01 |
| JP5938352B2 JP5938352B2 (ja) | 2016-06-22 |
Family
ID=43828318
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557294A Active JP5938352B2 (ja) | 2010-03-11 | 2011-03-11 | イミダゾピリジンｓｙｋ阻害剤 |
| JP2015094508A Expired - Fee Related JP6177828B2 (ja) | 2010-03-11 | 2015-05-05 | イミダゾピリジンｓｙｋ阻害剤 |
| JP2017136797A Withdrawn JP2017222685A (ja) | 2010-03-11 | 2017-07-13 | イミダゾピリジンｓｙｋ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015094508A Expired - Fee Related JP6177828B2 (ja) | 2010-03-11 | 2015-05-05 | イミダゾピリジンｓｙｋ阻害剤 |
| JP2017136797A Withdrawn JP2017222685A (ja) | 2010-03-11 | 2017-07-13 | イミダゾピリジンｓｙｋ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9562056B2 (enExample) |
| EP (1) | EP2545052B1 (enExample) |
| JP (3) | JP5938352B2 (enExample) |
| KR (1) | KR101717809B1 (enExample) |
| CN (1) | CN103168039B (enExample) |
| AU (3) | AU2011226689B2 (enExample) |
| BR (1) | BR112012022943A2 (enExample) |
| CA (1) | CA2792769C (enExample) |
| ES (1) | ES2530449T3 (enExample) |
| MX (1) | MX350010B (enExample) |
| NZ (1) | NZ602362A (enExample) |
| PT (1) | PT2545052E (enExample) |
| WO (1) | WO2011112995A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090221612A1 (en) | 2008-02-13 | 2009-09-03 | Mitchell Scott A | Certain substituted amides, method of making, and method of use thereof |
| WO2010068258A1 (en) | 2008-12-08 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Imidazopyrazine syk inhibitors |
| LT2716157T (lt) | 2008-12-08 | 2016-09-12 | Gilead Connecticut, Inc. | Imidazopirazino syk inhibitoriai |
| MX350010B (es) | 2010-03-11 | 2017-08-23 | Gilead Connecticut Inc | Inhibidores syk de imidazopiridinas. |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US8722676B2 (en) * | 2011-11-03 | 2014-05-13 | Genentech, Inc. | Bicyclic piperazine compounds |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| WO2013188856A1 (en) * | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| CN102898426B (zh) * | 2012-11-15 | 2015-04-22 | 江苏先声药业有限公司 | 抑制igf-1r酪氨酸激酶活性的吡啶并吡唑类衍生物 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| JP6153667B2 (ja) | 2013-07-30 | 2017-06-28 | ギリアード コネチカット， インコーポレイテッド | Ｓｋｙ阻害剤の製剤 |
| NZ715776A (en) | 2013-07-30 | 2017-04-28 | Gilead Connecticut Inc | Polymorph of syk inhibitors |
| CA2919479C (en) | 2013-07-31 | 2017-08-22 | Gilead Sciences, Inc. | Syk inhibitors |
| EP3076976B1 (en) | 2013-12-04 | 2020-09-02 | Gilead Sciences, Inc. | Methods for treating cancers |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| MX2017000610A (es) | 2014-07-14 | 2017-04-27 | Gilead Sciences Inc | Metodos combinados para tratar canceres. |
| TW201617074A (zh) * | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2017097671A1 (de) * | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
| WO2018053190A1 (en) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Syk inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US11091460B2 (en) | 2017-06-14 | 2021-08-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Syk inhibitor and use method therefor |
| US11384082B2 (en) | 2017-08-25 | 2022-07-12 | Kronos Bio, Inc. | Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US20230065740A1 (en) | 2018-12-28 | 2023-03-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| CN110183471B (zh) * | 2019-05-21 | 2022-02-15 | 江苏大学 | 一种哌嗪类衍生物及制备方法及应用 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN112010879B (zh) * | 2020-09-15 | 2021-07-02 | 山西大学 | 一种Zn功能配合物及其制备方法和应用 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN113636973B (zh) * | 2021-09-07 | 2023-04-07 | 山东铂源药业股份有限公司 | 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| KR20040068613A (ko) | 1994-03-25 | 2004-07-31 | 이소테크니카 인코포레이티드 | 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| FR2723373B1 (fr) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent |
| JPH11505524A (ja) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
| US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| SE9704404D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
| DK1146892T3 (da) * | 1999-01-25 | 2003-11-24 | Apoxis Sa | BAFF, inhibitorer deraf og deres anvendelse i modulationen af B-celle responset |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US6858613B2 (en) | 2002-02-19 | 2005-02-22 | Pfizer Inc. | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease |
| EP1509526A2 (en) | 2002-04-19 | 2005-03-02 | Cellular Genomics Inc. | Imidazo(1,2-a)pyrazin-8-ylamines, method of making, and method of use thereof |
| WO2004022562A1 (en) | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| MXPA05003058A (es) * | 2002-09-19 | 2005-05-27 | Schering Corp | Nuevas imidazopiridinas como inhibidores de cinasa dependientes de ciclina. |
| WO2004026877A1 (en) | 2002-09-23 | 2004-04-01 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| KR20060010709A (ko) | 2002-09-23 | 2006-02-02 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진 |
| WO2004072080A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity |
| AR043002A1 (es) | 2003-02-18 | 2005-07-13 | Altana Pharma Ag | Imidazopirazinas 6-substituidos |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US20060183746A1 (en) | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005019220A2 (en) | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| WO2005085252A1 (en) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| KR20070119606A (ko) | 2004-11-10 | 2007-12-20 | 씨지아이 파마슈티칼스, 인크. | 특정 이미다조[１,２-ａ]피라진-８-일아민, 그의 제조 방법및 용도 |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| BRPI0618520A2 (pt) | 2005-11-10 | 2011-09-06 | Schering Corp | imidazopirazinas como inibidores de proteìna cinase |
| TW200803863A (en) | 2005-11-10 | 2008-01-16 | Schering Corp | Method for inhibiting protein kinases |
| BRPI0716239A2 (pt) | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| US7951818B2 (en) * | 2006-12-01 | 2011-05-31 | Galapagos Nv | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases |
| CN101952283B (zh) | 2007-12-14 | 2013-04-17 | 霍夫曼-拉罗奇有限公司 | 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物 |
| US20090221612A1 (en) | 2008-02-13 | 2009-09-03 | Mitchell Scott A | Certain substituted amides, method of making, and method of use thereof |
| WO2009155388A1 (en) * | 2008-06-20 | 2009-12-23 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
| ES2552681T3 (es) * | 2008-07-15 | 2015-12-01 | F. Hoffmann-La Roche Ag | Nuevas fenil-imidazopiridinas y piridazinas |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| JPWO2010038257A1 (ja) * | 2008-09-30 | 2012-02-23 | 株式会社アドバンテスト | プログラマブルデバイス、およびデータ書込方法 |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| LT2716157T (lt) | 2008-12-08 | 2016-09-12 | Gilead Connecticut, Inc. | Imidazopirazino syk inhibitoriai |
| WO2010068258A1 (en) | 2008-12-08 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Imidazopyrazine syk inhibitors |
| MX350010B (es) | 2010-03-11 | 2017-08-23 | Gilead Connecticut Inc | Inhibidores syk de imidazopiridinas. |
| US20140148430A1 (en) | 2012-11-26 | 2014-05-29 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
| NZ715776A (en) | 2013-07-30 | 2017-04-28 | Gilead Connecticut Inc | Polymorph of syk inhibitors |
| JP6153667B2 (ja) | 2013-07-30 | 2017-06-28 | ギリアード コネチカット， インコーポレイテッド | Ｓｋｙ阻害剤の製剤 |
| CA2919479C (en) | 2013-07-31 | 2017-08-22 | Gilead Sciences, Inc. | Syk inhibitors |
| EP3076976B1 (en) | 2013-12-04 | 2020-09-02 | Gilead Sciences, Inc. | Methods for treating cancers |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| MX2017000610A (es) | 2014-07-14 | 2017-04-27 | Gilead Sciences Inc | Metodos combinados para tratar canceres. |
| TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| WO2016172117A1 (en) | 2015-04-21 | 2016-10-27 | Gilead Sciences, Inc. | Treatment of chronic graft versus host disease with syk inhibitors |
| WO2018053190A1 (en) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Syk inhibitors |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
-
2011
- 2011-03-11 MX MX2012010418A patent/MX350010B/es active IP Right Grant
- 2011-03-11 EP EP11709600.8A patent/EP2545052B1/en active Active
- 2011-03-11 JP JP2012557294A patent/JP5938352B2/ja active Active
- 2011-03-11 ES ES11709600T patent/ES2530449T3/es active Active
- 2011-03-11 NZ NZ602362A patent/NZ602362A/en not_active IP Right Cessation
- 2011-03-11 KR KR1020127026472A patent/KR101717809B1/ko not_active Expired - Fee Related
- 2011-03-11 AU AU2011226689A patent/AU2011226689B2/en active Active
- 2011-03-11 CN CN201180023252.0A patent/CN103168039B/zh not_active Expired - Fee Related
- 2011-03-11 CA CA2792769A patent/CA2792769C/en active Active
- 2011-03-11 BR BR112012022943A patent/BR112012022943A2/pt not_active Application Discontinuation
- 2011-03-11 WO PCT/US2011/028194 patent/WO2011112995A1/en not_active Ceased
- 2011-03-11 US US13/806,094 patent/US9562056B2/en not_active Expired - Fee Related
- 2011-03-11 PT PT117096008T patent/PT2545052E/pt unknown
-
2015
- 2015-05-05 JP JP2015094508A patent/JP6177828B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-23 AU AU2016219585A patent/AU2016219585B2/en active Active
- 2016-12-21 US US15/387,557 patent/US10092583B2/en active Active
-
2017
- 2017-07-13 JP JP2017136797A patent/JP2017222685A/ja not_active Withdrawn
-
2018
- 2018-05-08 AU AU2018203210A patent/AU2018203210A1/en not_active Abandoned
- 2018-09-06 US US16/124,113 patent/US10842803B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522238A5 (enExample) | ||
| US11753407B2 (en) | Compounds for treating spinal muscular atrophy | |
| JP2012510998A5 (enExample) | ||
| EP3875078A1 (en) | Compounds for the treatment of covid-19 | |
| KR20140128310A (ko) | 척수성 근위축증을 치료하기 위한 화합물 | |
| WO2012068096A2 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
| JP2010507577A (ja) | トリアゾロピリダジンタンパク質キナーゼモジュレーター | |
| AU2011226689A1 (en) | Imidazopyridines Syk inhibitors | |
| JP2013518890A5 (enExample) | ||
| CN103459384A (zh) | 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用和制造方法 | |
| WO2021142026A1 (en) | Shp2 inhibitor dosing and methods of treating cancer | |
| NZ575336A (en) | Bicyclic triazoles as protein kinase modulators | |
| AU2010249790A1 (en) | Benzoxazepines based P13K/mT0R inhibitors against proliferative diseases | |
| KR20160037198A (ko) | Syk 억제제 | |
| RU2012152548A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
| JP2023548657A (ja) | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 | |
| JPWO2020005877A5 (enExample) | ||
| JP2015534981A5 (enExample) | ||
| JPWO2020065613A5 (enExample) | ||
| JPWO2020065614A5 (enExample) |